Bionano Genomics (NASDAQ:BNGO) Trading Down 1.7% – Here’s What Happened

Bionano Genomics, Inc. (NASDAQ:BNGO) was down 1.7% on Tuesday . The company traded as low as $1.13 and last traded at $1.14. 91,052 shares changed hands during trading, a decline of 30% from the average session volume of 130,080 shares. The stock had previously closed at $1.16.

Analyst Ratings Changes

A number of analysts have commented on BNGO shares. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a research report on Saturday, June 13th. HC Wainwright lowered their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.00.

Bionano Genomics Price Performance

The company has a quick ratio of 1.59, a current ratio of 1.84 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average price is $1.19 and its two-hundred day moving average price is $1.26. The firm has a market capitalization of $13.08 million, a price-to-earnings ratio of -0.26 and a beta of 1.62.

Bionano Genomics (NASDAQ:BNGO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.12. The firm had revenue of $6.69 million during the quarter, compared to analysts’ expectations of $6.57 million. Bionano Genomics had a negative net margin of 109.94% and a negative return on equity of 71.38%. Analysts anticipate that Bionano Genomics, Inc. will post -2.49 EPS for the current fiscal year.

Institutional Trading of Bionano Genomics

Several institutional investors have recently bought and sold shares of BNGO. Jane Street Group LLC bought a new position in Bionano Genomics in the fourth quarter valued at approximately $34,000. Renaissance Technologies LLC raised its position in shares of Bionano Genomics by 31.6% during the 1st quarter. Renaissance Technologies LLC now owns 48,700 shares of the company’s stock valued at $57,000 after acquiring an additional 11,700 shares during the last quarter. Carret Asset Management LLC lifted its stake in shares of Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares during the period. Geode Capital Management LLC boosted its position in shares of Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after purchasing an additional 39,928 shares during the last quarter. Finally, DRW Securities LLC bought a new position in shares of Bionano Genomics in the 4th quarter worth $258,000. Institutional investors and hedge funds own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.